Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders... Show more
a developer of non-invasive therapies for psychiatric and neurological disorders
Industry MedicalNursingServices
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BCHI | 26.72 | N/A | N/A |
| GMO Beyond China ETF | |||
| RSPN | 59.12 | -0.18 | -0.30% |
| Invesco S&P 500 Equal Weight Industrials ETF (RSPN) | |||
| VLUE | 201.10 | -1.60 | -0.79% |
| iShares MSCI USA Value Factor ETF (VLUE) | |||
| DMB | 9.76 | -0.08 | -0.81% |
| BNY Mellon Municipal | |||
| FLAX | 37.04 | -0.75 | -1.98% |
| Franklin FTSE Asia ex Japan ETF (FLAX) | |||
A.I.dvisor indicates that over the last year, STIM has been loosely correlated with CBLL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if STIM jumps, then CBLL could also see price increases.
| Ticker / NAME | Correlation To STIM | 1D Price Change % | ||
|---|---|---|---|---|
| STIM | 100% | -1.03% | ||
| CBLL - STIM | 33% Loosely correlated | -2.60% | ||
| CVRX - STIM | 28% Poorly correlated | -5.88% | ||
| ALGN - STIM | 27% Poorly correlated | -3.34% | ||
| BMRA - STIM | 26% Poorly correlated | -6.29% | ||
| NEO - STIM | 26% Poorly correlated | -2.81% | ||
More | ||||
| Ticker / NAME | Correlation To STIM | 1D Price Change % |
|---|---|---|
| STIM | 100% | -1.03% |
| Health Services category (241 stocks) | -1% Poorly correlated | -0.69% |
| Medical/Nursing Services category (140 stocks) | -2% Poorly correlated | -0.14% |
The 10-day RSI Oscillator for STIM moved out of overbought territory on August 18, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 instances where the indicator moved out of the overbought zone. In 32 of the 35 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STIM as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for STIM turned negative on August 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STIM entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 57 cases where STIM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where STIM advanced for three days, in 226 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. STIM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.300) is normal, around the industry mean (11.051). P/E Ratio (0.000) is within average values for comparable stocks, (99.772). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.057). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.250) is also within normal values, averaging (39.828).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.